Navigation Links
Repligen Reports Second Quarter Fiscal Year 2011 Financial Results
Date:11/2/2010

WALTHAM, Mass., Nov. 2, 2010 /PRNewswire-FirstCall/ -- Repligen Corporation (Nasdaq: RGEN) today reported results for the second quarter of fiscal year 2011, ended September 30, 2010.  Total revenue for the second quarter was $7,307,000 compared to total revenue of $5,421,000 for the second quarter of fiscal year 2010, an increase of $1,886,000 or 35%.  Bioprocessing product revenue for the second quarter was $4,416,000 compared to $2,742,000 for the second quarter of fiscal 2010, an increase of $1,674,000 or 61%.  Royalty and research revenue for the second quarter, which consisted primarily of royalty payments from Bristol-Myers Squibb on the U.S. sales of Orencia®, was $2,891,000 compared to $2,679,000 for the same quarter in the prior year.

Operating expenses for the second quarter were $6,780,000 compared to $6,627,000 for the second quarter of fiscal year 2010.  Net income for the second quarter was $623,000 or $0.02 per diluted share, compared to a net loss for the second quarter of fiscal year 2010 of $980,000 or $0.03 per diluted share.  Cash, cash equivalents and marketable securities as of September 30, 2010 were $59,691,000 compared to $59,146,000 as of March 31, 2010.

"We are pleased to have achieved strong growth in our bioprocessing business for the quarter," stated Walter C. Herlihy, President and Chief Executive Officer of Repligen Corporation.  "We are focused on completing our Phase 3 study for pancreatic imaging and our Phase 2b study for bipolar depression, and we look forward to reporting the top-line results for both of these studies in the first quarter of 2011."

For the six-month period ended September 30, 2010, total revenue was $14,317,000 compared to $10,481,000 for the same period in fiscal year 2010.  Operating expenses for the six-month period ended September 30, 2010 were $12,901,
'/>"/>

SOURCE Repligen Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related biology technology :

1. Repligen Receives Research Grants to Support Friedreichs Ataxia Development Program
2. Repligen Announces Publication of Positive Results with Proprietary HDAC Inhibitor in Huntingtons Disease Model
3. Repligen to Present at the 2008 UBS Global Life Sciences Conference Wednesday, September 24th, 1:00 p.m. EDT
4. Repligen to Present at the Rodman & Renshaw 10th Annual Healthcare Conference Monday, November 10th, 4:55 p.m. EST
5. Repligen Announces Conference Call of Third Quarter Fiscal Year 2009 Results
6. Repligen to Present at the BIO CEO & Investor Conference Monday, February 9th, 11:30 a.m. EST
7. Repligen Reports Third Quarter Fiscal Year 2009 Financial Results
8. Repligen to Present at the Cowen and Company 29th Annual Healthcare Conference Monday, March 16th, 2:25 p.m. EDT
9. Repligen Announces Conference Call of Fourth Quarter and Fiscal Year 2009 Results
10. Repligen Reports Fourth Quarter and Fiscal Year 2009 Financial Results
11. Repligen Announces Conference Call of First Quarter Fiscal Year 2010 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/29/2015)... Md. , June 29, 2015  Neuralstem, Inc. ... cell technology to develop small molecule and cell therapy ... it has been approved for listing on the NASDAQ ... stock will continue to trade on the NYSE MKT ... on the NASDAQ Capital Market is expected to commence ...
(Date:6/29/2015)... 2015 Elsevier , a ... and services, today announced the highlights of its journal ... Journal Citation Reports® (JCR) published by Thomson Reuters, Elsevier ... 2013 to 2014, ahead of the aggregate across other ... in 62 subject categories, up from 61 in 2013. ...
(Date:6/26/2015)...  A San Francisco company, Pembient, recently announced it ... horn: beer in China and ... response to the emerging industry, two leading rhino conservation ... synthetic rhino horn.  The International ... International (SRI) released a joint statement ...
(Date:6/26/2015)... 2015 The report "Biolubricants Market ... Metalworking fluids, Chainsaw oils, Mold Release Agents), End Use ... Global trends and Forecasts to 2020" published by MarketsandMarkets, ... by 2020 at a CAGR of 6.27% between 2015 ... Tables and   66 Figures spread through 170 Pages ...
Breaking Biology Technology:Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 2Neuralstem, Inc. Announces Approval for Listing on the NASDAQ Capital Market 3Elsevier Announces 2014 Citation Impact Highlights 2Elsevier Announces 2014 Citation Impact Highlights 3Rhino Experts Oppose Synthetic Rhino Horn as Solution to Poaching Crisis 2Biolubricants Market Worth $2,972.13 Million by 2020 2Biolubricants Market Worth $2,972.13 Million by 2020 3
... Calif., July 27, 2011 Sangamo BioSciences, Inc. (Nasdaq: ... and accomplishments. For the second quarter ended ... $10.3 million, or $0.20 per share, compared to a net ... same period in 2010. As of June 30, 2011, the ...
... Corporation , a leading global provider of microwave laboratory ... microwave peptide synthesis products . In FY2011 year-to-date, the ... in its automated peptide synthesizer instrument sales and is ... systems. Additionally, CEM,s products were well received at the ...
... 2011 Linden LLC, a Chicago-based healthcare private ... an investment in Strata Pathology Services, Inc., a ... Headquartered in Lexington, Massachusetts, Strata offers ... oral pathology, gastroenterology and gynecology segments. Since 1984, ...
Cached Biology Technology:Sangamo BioSciences Reports Second Quarter 2011 Financial Results 2Sangamo BioSciences Reports Second Quarter 2011 Financial Results 3Sangamo BioSciences Reports Second Quarter 2011 Financial Results 4Sangamo BioSciences Reports Second Quarter 2011 Financial Results 5Sangamo BioSciences Reports Second Quarter 2011 Financial Results 6Sangamo BioSciences Reports Second Quarter 2011 Financial Results 7Record Year for CEM's Peptide Synthesis Business 2Record Year for CEM's Peptide Synthesis Business 3Linden Enters Anatomic Pathology Sector Through Investment in Strata Pathology Services, Inc. 2
(Date:6/25/2015)... , June 25, 2015  TAKE Solutions Ltd., ... patent by the United States Patent and Trademark Office ... This process leverages TAKE Solutions, Clinical Accelerators to reduce ... 50% (when compared to standardization without the accelerators), thus ... At the heart of the ...
(Date:6/24/2015)... Biometry authentication provider KeyLemon today announced ... one face in. Logo - ... in, entering the expanding biometric authentication market in ... answer to the password problem. With advanced face ... KeyLemon, one face in allows users to securely ...
(Date:6/18/2015)... , June 18, 2015 This report ... Million by the following Product Segments, which includes Immunoassay ... Chemiluminescence Immunoassay Systems, Radio Immunoassay Systems, and Nephelometric Immunoassay ... US, Canada , Japan ... Asia-Pacific , Latin America , ...
Breaking Biology News(10 mins):TAKE Solutions Awarded Patent By USPTO 2KeyLemon Announces Partnership With Biometric Password Solution onefacein 2Global Immunoassay Systems Market 2Global Immunoassay Systems Market 3Global Immunoassay Systems Market 4Global Immunoassay Systems Market 5Global Immunoassay Systems Market 6Global Immunoassay Systems Market 7Global Immunoassay Systems Market 8Global Immunoassay Systems Market 9Global Immunoassay Systems Market 10Global Immunoassay Systems Market 11Global Immunoassay Systems Market 12Global Immunoassay Systems Market 13Global Immunoassay Systems Market 14Global Immunoassay Systems Market 15Global Immunoassay Systems Market 16Global Immunoassay Systems Market 17Global Immunoassay Systems Market 18Global Immunoassay Systems Market 19Global Immunoassay Systems Market 20Global Immunoassay Systems Market 21Global Immunoassay Systems Market 22Global Immunoassay Systems Market 23Global Immunoassay Systems Market 24Global Immunoassay Systems Market 25Global Immunoassay Systems Market 26Global Immunoassay Systems Market 27Global Immunoassay Systems Market 28Global Immunoassay Systems Market 29
... Madison, WI, February 24, 2009 | Tiny sediment grains ... minerals in an open fabric that results in a ... grains. Scientists at the U.S. Geological Survey (USGS) are ... composition of these coatings on sediment grains in the ...
... with the tiny fruit fly and then moving into mice and ... of the same gene suppresses cancer in all three organisms. Reciprocally, ... in mammals leads to cancer. The authors show there is ... with a drug. They report their findings in two papers in ...
... today (Monday) to advise the country on how it ... The biotechonology experts from the Belfast-based University are ... cost the world economy around $200 billion in lost ... year. A delegation led by Dr Gerry Brennan ...
Cached Biology News:Ultra-fine coatings on sediment grains influence nitrate and sulfate storage in soil 2Suppressing cancer with a master control gene 2Reduction in parasite infections ahead for India 2